Fig. 1 · Structure

Documents & Downloads

Indole-3-carbinol

Cat. No. A10473 CAS 700-06-1
Indole-3-carbinol is produced by the breakdown of the glucosinolate glucobrassicin, which can be found at relatively high levels in cruciferous vegetables.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Indole-3-carbinol (I3C) inhibited purified human neutrophil elastase noncompetitively in two substrate systems. Reported Ki values were 10.73 ± 0.04 µM for cyclin E processing and 12.93 ± 0.4 µM for chromogenic MetS hydrolysis. These are enzyme inhibition constants, not cellular treatment concentrations or IC50 values. [1]

I3C also bound the recombinant WWP1 HECT domain in a microscale thermophoresis assay: Figure 5B reported Kd = 446.5 nM for wild type and 7719 nM for the F577/Y656A mutant. This binding result alone does not establish catalytic potency or cellular target selectivity. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
NF-κB  
AhR  
Human Endogenous Metabolite  

Cellular Effect

Cell Line Activity Value Description Reference
U-251 EC50 390 μM Cytotoxicity against human U251 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay [PMID: 28256372]
U-87MG ATCC EC50 290 μM Cytotoxicity against human U87 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay [PMID: 28256372]
U-87MG ATCC IC50 526 μM Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth after 48 hrs by MTS assay [PMID: 23419325]

Indole-3-carbinol Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Indole-3-carbinol from 3 published references.

Indole-3-carbinol In Vitro Studies

In MDA-MB-231 breast cancer cells, 100 µM I3C for 48 h favored full-length 50-kDa cyclin E and increased the G1 DNA-content fraction. Elastase siRNA produced similar changes relative to transfection and scrambled-siRNA controls, supporting a contribution of elastase to this response without establishing an exclusive mechanism. [1]

Noncompetitive inhibition of human neutrophil elastase

Biochemical assay · Purified human neutrophil elastase with in vitro produced cyclin E or chromogenic MetS substrate [1]

Kinetic analyses using two substrates supported noncompetitive inhibition. The reported constants are Ki values, not cellular IC50 values. Cyclin E processing controls included DMSO, absence of elastase, and known elastase inhibitors (Figure 1B–C).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of elastase-mediated cyclin E processingKi 10.73 ± 0.04 µM[1]
Inhibition of chromogenic MetS hydrolysis by elastaseKi 12.93 ± 0.4 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Cyclin E kinetic series: 0, 15, 25 and 50 µM I3C (Figure 3A–B). MetS series: 0, 25, 50 and 100 µM I3C (Figure 3C).
Exposure duration
Cyclin E assay: 5 min; chromogenic assay duration not established from retrieved main text.
Method
Cell-free enzyme assays
Vehicle
DMSO control
Reported limits
SI kinetic protocol not retrieved; replicate n and meaning of Ki ± terms not defined in the retrieved main text. Main Methods specifies 30 °C for cyclin E digestion whereas Figure 3 caption specifies 37 °C; no temperature-specific potency claim is made.
Methods and source locations

Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C

Evidence concerns the material described in the paper; it does not validate an Adooq lot. No salt conversion or derivative equivalence assumed.

Results: I3C Acts as a Noncompetitive Inhibitor; Figure 3A–C and caption; main Methods: cyclin E processing assay

Inhibition of elastase-mediated cyclin E processing: Western blot densitometry of remaining 50-kDa cyclin E; Dixon plot analysis — Results: I3C Acts as a Noncompetitive Inhibitor; Figure 3A–C and caption; main Methods: cyclin E processing assay

Inhibition of chromogenic MetS hydrolysis by elastase: Spectrophotometric substrate hydrolysis; Dixon plot analysis — Results kinetic analysis; Figure 3C and caption

Elastase knockdown phenocopies I3C-associated cell-cycle effects

Cell-based study · MDA-MB-231 human breast cancer cells; transfection, scrambled-siRNA and elastase-siRNA controls [1]

I3C treatment and elastase knockdown each favored the 50-kDa cyclin E form and increased the G1 fraction. The combined condition retained an additional effect, consistent with elastase contributing to, rather than fully accounting for, I3C responses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cyclin E protein formsQualitative Western blot I3C and elastase siRNA each shifted cyclin E toward the 50-kDa form relative to DMSO/transfection controls.[1]
G1 DNA-content fraction in representative flow-cytometry panels% G1 Transfection control: 51.3%; control + I3C: 67.6%; scrambled siRNA: 52.5%; scrambled siRNA + I3C: 67.3%; elastase siRNA: 71.0%; elastase siRNA + I3C: 73.0%.[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 µM I3C
Exposure duration
48 h I3C exposure after 24 h siRNA/transfection period
Method
Treatment of transfection-control, scrambled-siRNA and elastase-siRNA groups, with or without I3C
Vehicle
DMSO
Reported limits
Full cell-culture details reside in SI, which was not retrieved. Figure 4C values are representative panel values; biological replicate n and uncertainty for those percentages are not specified in the retrieved main text.
Methods and source locations

Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C

Evidence concerns the material described in the paper; it does not validate an Adooq lot. No salt conversion or derivative equivalence assumed.

Results: siRNA Knockdown of Cellular Elastase Levels; Figure 4A–C and caption; Methods: siRNA Knockdown of Cellular Elastase Levels

Cyclin E protein forms: Western blot; Hsp90 loading control — Figure 4B and caption; accompanying Results

G1 DNA-content fraction in representative flow-cytometry panels: Propidium iodide DNA-content flow cytometry — Figure 4C labels and caption

Binding to the WWP1 HECT domain

Biochemical assay · Fluorescently labeled recombinant His-WWP1 HECT wild type and F577/Y656A mutant [2]

Microscale thermophoresis showed binding to the wild-type HECT domain and weaker apparent affinity for the double mutant. Binding constants do not constitute catalytic IC50 values or prove cellular target selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
I3C binding to wild-type WWP1 HECT domainKd 446.5 nM (Figure 5B; Results rounds to 450 nM)[2]
I3C binding to WWP1 HECT F577/Y656A mutantKd 7719 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Methods describes a two-fold I3C dilution series from 7.63 nM to 250,000 nM, mixed 1:1 with labeled WWP1.
Exposure duration
Measurement incubation duration not specified in the retrieved MST Methods.
Method
MST at 25 °C in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol
Reported limits
Independent replicate n, fitted uncertainty and a separate compound-only fluorescence control are not stated in the retrieved MST description. The dilution-series wording does not explicitly distinguish premix from final concentration, so no revised final range is inferred.
Methods and source locations

Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C

Evidence concerns the material described in the paper; it does not validate an Adooq lot. No salt conversion or derivative equivalence assumed.

Results: Identification of indole-3-carbinol as a WWP1 inhibitor; Figure 5B and caption; Methods: Reagents; Protein labeling and microscale thermophoresis (MST) analysis

I3C binding to wild-type WWP1 HECT domain: Microscale thermophoresis using MONOLITH NT.115 — Results: Identification of indole-3-carbinol as a WWP1 inhibitor; Figure 5B and caption; Methods: Reagents; Protein labeling and microscale thermophoresis (MST) analysis

I3C binding to WWP1 HECT F577/Y656A mutant: Microscale thermophoresis; mutant comparator — Figure 5B and caption; Results identification of I3C as WWP1 inhibitor

Indole-3-carbinol In Vivo Studies

In male athymic BALB/c nu/nu mice, a diet containing 1 µmol I3C/g reduced LNCaP xenograft growth relative to control diet (reported growth-curve comparison p < 0.0001; nine animals per group). Methods describes dietary exposure beginning two weeks before implantation and continuing for seven weeks afterward. The study does not establish treatment efficacy for pre-existing tumors, causal microbiome mediation, or a safety margin; dietary I3C may also generate condensation products such as DIM. [3]

Dietary I3C and LNCaP xenograft growth

Animal study · Male athymic BALB/c nu/nu mice bearing bilateral LNCaP human prostate cancer xenografts; nine animals per diet group [3]

Dietary I3C was associated with slower tumor growth than control diet. Methods describes two weeks of dietary intervention before implantation and seven weeks afterward; this design does not establish efficacy against pre-existing tumors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor-volume trajectories over seven weeks after implantationComparison of growth curves p < 0.0001; lower tumor growth with I3C diet[3]

Conditions shared by the study groups

Route
Oral, in diet
Frequency
Ad libitum
Treatment course
Two weeks before LNCaP implantation and seven weeks afterward (Methods 2.2)
Vehicle
Basal diet (AIN-93 named in abstract)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
I3C-containing diet versus control diet
1 µmol I3C/g diet
Diet without added I3CLower tumor-volume growth curve with I3C; p < 0.0001 for comparison of fits[3]
I3C-containing diet versus control diet
Model: Male athymic BALB/c nu/nu mice; nine animals per group
Reported limits: No mg/kg conversion made. Bilateral-tumor aggregation and Figure 4A error-bar semantics not specified in caption.
Methods and source locations

Compound reported in the paper: Indole-3-carbinol; Compound label in the paper: I3C

Evidence concerns the material described in the paper; it does not validate an Adooq lot. Dietary exposure may include acid-condensation products such as DIM.

Methods 2.1 Animals and Diet, 2.2 Tumor Xenograft Model; Results 3.3; Figure 4A and caption

Tumor-volume trajectories over seven weeks after implantation: Weekly tumor measurement; Figure 4 caption specifies nonlinear fitting and comparison of fits — Results 3.3; Figure 4A/caption

I3C-containing diet versus control diet · Methods 2.1 Animals and Diet, 2.2 Tumor Xenograft Model; Results 3.3; Figure 4A and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 700-06-1
Formula C9H9NO
Molecular Weight 147.2
Synonyms 3-Indolemethanol; Indole-3-methanol
SMILES
C1=CC=C2C(=C1)C(=CN2)CO

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 28 mg/mL (190.24 mM)
Water 7 mg/mL (47.56 mM)
Ethanol 28 mg/mL (190.24 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Indole-3-carbinol Research References

  1. [1] Hanh H Nguyen, Ida Aronchik, Gloria A Brar, et al. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing Proceedings of the National Academy of Sciences of the United States of America (2008). PMID: 19064917 DOI: 10.1073/pnas.0806581105 Source material
  2. [2] Yu-Ru Lee, Ming Chen, Jonathan D Lee, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway Science (2019). PMID: 31097636 DOI: 10.1126/science.aau0159 Source material
  3. [3] Yanbei Wu, Robert W Li, Haiqiu Huang, et al. Inhibition of Tumor Growth by Dietary Indole-3-Carbinol in a Prostate Cancer Xenograft Model May Be Associated with Disrupted Gut Microbial Interactions Nutrients (2019). PMID: 30813350 DOI: 10.3390/nu11020467 Source material

Added to your cart

View Cart Checkout
Loading...